Cryoport’s 2025 Playbook: Revenue Rises, Margins Hold, and CGT Momentum Keeps the Engine Warm

Cryoport, Inc. (CYRX) delivers full-year 2025 results that read more like a financing memo than a drama, with revenue climbing to a respectable $176.2 million and a clear path toward higher 2026 revenue. This isn’t a tale of one big consumer revival; it’s a narrative about expanding service streams in the life sciences supply chain, from CGT support to clinical trials, and a tangible push toward profitability finesse.

What Cryoport disclosed: the cold facts behind the numbers

Cryoport reported FY 2025 revenue of $176.2 million, noting it exceeded the high end of prior guidance. The company highlighted several moving parts within its mix:

Life Sciences Services revenue rose 18% year-over-year for the year, with BioStorage/BioServices up 22%.
Commercial cell and gene therapy (CGT) revenue grew 29% year-over-year to $33.4 million in FY 2025.
Clinical trial support revenue totaled $47.1 million for FY 2025.
Cryoport supported a record 760 global clinical trials as of December 31, 2025.
Full-year 2026 revenue guidance implies 8%-10% growth year over year, a revenue forecast of about $190 million to $194 million.
Gross margin stood at 47%, and management pointed to a $12 million year-over-year improvement in adjusted EBITDA from continuing operations, aided by cost-reduction initiatives.

In a year characterized by macro headwinds, Cryoport framed its results as a blend of durable demand signals—CGT activity, clinical trial support, and a growing multi-channel service footprint—and disciplined execution on costs.

The management voice: leadership commentary and what it portends

CEO Jerrell Shelton framed 2025 as a year of “strong progress” across core markets. He highlighted:

Double-digit revenue growth driven by CGT activity and expansion of revenue per client.
A multi-year push to broaden the revenue base beyond services, leveraging Cryoport’s end-to-end temperature-controlled capabilities.
Operational discipline that contributed to a healthier gross margin and a meaningful year-over-year EBITDA improvement.

Important nuance: the company’s disclosures emphasize revenue and adjusted EBITDA, not conventional GAAP earnings per share (EPS). For investors, that means EPS consensus and any earnings surprise relative to Street estimates remain to be seen until analysts weigh in with their numbers. The lack of an explicit EPS figure in this release makes the EPS forecast and potential earnings surprise contingent on forward-looking estimates rather than reported results alone. Still, the narrative around margin improvement and free-cash-fluidity could shape how investors model Cryoport’s path to profitability.

Product and segment highlights: where the growth levers sit

Beyond the headline revenue number, Cryoport’s segment commentary underscores a few key growth drivers:

CGT support revenue: a 29% YoY increase in FY 2025, suggesting burgeoning demand for CGT-related logistics as commercial therapies scale.
Clinical trials support: 47.1 million in FY 2025, with 760 global trials supported at year end, a signal of Cryoport’s entrenched position in the clinical development ecosystem.
BioStorage/BioServices: a robust growth arc within Life Sciences Services, indicative of customers’ ongoing need for specialized cold-chain capacity.
Capital equipment and solutions: MVE Biological Solutions remains a note of potential expansion with new offerings like Condition Monitoring Solutions and the Fusion 800 Series freezer, widening Cryoport’s technology-enabled service portfolio.

These dynamics paint a picture of a business that is expanding its revenue mix through both services and products, with investors watching whether this mix can translate into durable gross margins and sustained EBITDA leverage as the revenue base compounds.

Guidance and what it means for the sector

The firm provided a 2026 revenue forecast in the range of $190 million to $194 million, implying 8%-10% growth versus FY 2025. In the current market context, a mid-to-high single-digit growth trajectory paired with margin discipline can be a meaningful blueprint for peers navigating CGT supply chain scale, clinical trial uptake, and the regulatory environment.

On a broader industry level, Cryoport’s emphasis on expanding client revenue per engagement and expanding high-end cold-chain capacity hints at a broader shift: as CGT programs mature and commercial launches accelerate, the value of integrated supply chain solutions—especially those with strong data and monitoring capabilities—may become a more material driver of profitability. Investors may keep an eye on whether this multi-pronged growth approach, coupled with cost controls, can sustain the ratio of gross margin around the high-40s and push EBITDA margins higher over time.

Takeaways for Cryoport and its peers

Revenue momentum is real, driven by CGT support and clinical trial services, with a clear tailwind from a growing CGT ecosystem.
Gross margin of 47% and a $12 million uplift in adjusted EBITDA signal that Cryoport is translating volume into better unit economics, not just headcount growth.
The 2026 revenue forecast indicates a steady but not explosive growth path; the market will test whether cost discipline can be sustained alongside top-line expansion.
Analyst expectations around EPS and consensus will hinge on future quarterly disclosures and the company’s ability to convert revenue growth into meaningful earnings per share gains or EBITDA progression.
For peers, Cryoport’s push into monitoring solutions and higher-end equipment (Fusion 800 Series) underscores an industry trend toward integrated product and service platforms, potentially rewarding incumbents with higher switching costs and data-enabled efficiencies.

Final notes: what to watch next

As Cryoport enters 2026 with a revenue forecast in the $190–$194 million band and a focus on cost discipline, the Street will be keen on two things: (i) whether EPS translates from EBITDA gains into meaningful earnings power, and (ii) whether the CGT and BioStorage/BioServices tailwinds persist long enough to support sustained margin expansion. In the meantime, the company’s narrative about leadership in CGT logistics, combined with portfolio expansion into monitoring and high-end cryogenic appliances, creates a plausible runway for Cryoport to extend its market advantage—assuming macro conditions cooperate and customers keep flocking to a single, proven cold-chain partner.

Bottom line: the story isn’t just “revenue up” or “guidance up.” It’s a strategic bet that Cryoport can keep combining growth in services with smarter cost management to turn a rising tide into a durable earnings cadence—something readers and rivals will be parsing as the year unfolds.